{
  "docId": "019de513-bbaf-7632-8c51-2e65d00dc762",
  "docSlug": "d61504792622527e2ff1c803565a1f5e",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 42 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 42,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 48,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de513-bbaf-7632-8c51-2e65d00dc762/31",
  "deckHref": "/decks/019de513-bbaf-7632-8c51-2e65d00dc762",
  "deckJsonHref": "/decks/019de513-bbaf-7632-8c51-2e65d00dc762.json",
  "deckAnchorHref": "/decks/019de513-bbaf-7632-8c51-2e65d00dc762#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.035,
        "w": 0.54,
        "x": 0.15,
        "y": 0.946
      },
      "kind": "source-note",
      "text": "1. Products with sales outside the United States impacted by F/X changes.\n2. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.\n3. On a proforma basis after giving effect to the IPO.",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46e7fd99-64f7-4645-bc6c-1bd517f6330d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.69,
        "w": 0.839,
        "x": 0.074,
        "y": 0.166
      },
      "kind": "table",
      "text": "Bausch + Lomb 2Q22-1Q22 2Q21-1Q21 Reported Change Constant Currency2 Organic Change2 Vision Care Revenue $1,149M $1,112M 3% 8% 8% Surgical Revenue $358M $347M 3% 8% 10% Ophthalmic Pharmaceuticals Revenue $323M $356M (9%) (6%) (6%) Total Revenue $1,830M $1,815M 1% 5% 5% Gross Profit $974M $959M 2% 5% Gross Margin 53.2% 52.8% 40 bps R&D $152M $138M (10%) (13%) R&D percent of Revenues 8.3% 7.6% SG&A $711M $676M (5%) (9%) SG&A percent of Revenues 38.9% 37.2% Operating Income $110M $143M (23%) (17%) Depreciation $64M $64M 0% 5% Stock Based Compensation $27M $29M (7%) (7%) Net Income $25M $71M (65%) (59%) Net Income Margin 1.4% 3.9% EPS3 $0.07 $0.20",
      "attrs": {},
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49b2c7ea-169d-4b6a-b9ea-f9326a2719a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.62,
        "x": 0.048,
        "y": 0.048
      },
      "kind": "title",
      "text": "Total Bausch + Lomb P&L¹ (GAAP) - YTD",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2947667-09ef-46f3-8473-e16e4d292500",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}